13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001440771
Total reported value
$177.3M
$177.3M
20 檔
55.4%
The Q1 2024 SEC filing reveals that Stonepine Capital Management, LLC held a total portfolio value of $177.3M, covering 20 public equity positions.
Stonepine Capital Management, LLC executed strategic sector rebalancing during Q1 2024, establishing 8 new positions while fully exiting 4 holdings and trimming 7 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EOLS | Evolus Inc | Stock-Other | 29.70% | +4.41% | -49.85% | |
| 2 | ADMA | Adma Biologics Inc | Stock-Healthcare | 17.94% | +1.16% | -62.84% | |
| 3 | ✓ | Alimera Sciences Inc | Stock-Other | 12.53% | — | +1.29% | |
| 4 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 10.05% | — | +50.32% | |
| 5 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 7.71% | — | — | |
| 6 | XOMA | Xoma Royalty Corporation | Stock-Other | 4.84% | -0.87% | EXIT | |
| 7 | TELA | Tela Bio Inc | Stock-Other | 3.10% | +0.48% | +116.56% | |
| 8 | NKTREUR | Nektar Therapeutics | Stock-Other | 2.58% | — | — | |
| 9 | MIST | Milestone Pharmaceuticals In | Stock-Other | 2.08% | — | — | |
| 10 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.78% | — | — | |
| 11 | CALC | Calcimedica Inc | Stock-Other | 1.72% | +0.31% | NEW | |
| 12 | ANIK | Anika Therapeutics Inc | Stock-Other | 1.23% | — | — | |
| 13 | RIGLUSD | Rigel Pharmaceuticals Inc | Stock-Other | 1.22% | — | — | |
| 14 | AYTU | Aytu Biopharma Inc | Stock-Other | 1.14% | +0.24% | — | |
| 15 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 1.05% | +0.44% | -89.93% | |
| 16 | XGN | Exagen Inc | Stock-Other | 0.49% | — | -42.57% | |
| 17 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.26% | — | — | |
| 18 | RZLT | Rezolute Inc | Stock-Other | 0.25% | — | -95.61% | |
| 19 | IOBTQ | Io Biotech Inc | Stock-Other | 0.21% | — | -90.63% | |
| 20 | SCYXEUR | Scynexis Inc | Stock-Other | 0.11% | — | -92.94% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVNCEUR | Revance Therapeutics Inc | +7.7% | NEW | New buy |
| 2 | LKFT | Lakefront Biotherapeutic-adr | +5.5% | +50.32% | Add |
| 3 | EOLS | Evolus Inc | +5.4% | -49.85% | Trim |
| 4 | ✓ | Alimera Sciences Inc | +5.1% | +1.29% | Add |
| 5 | XOMA | Xoma Royalty Corporation | +2.8% | +1.51% | Add |
| 6 | NKTREUR | Nektar Therapeutics | +2.6% | NEW | New buy |
| 7 | TELA | Tela Bio Inc | +2.2% | +116.56% | Add |
| 8 | MIST | Milestone Pharmaceuticals In | +2.1% | NEW | New buy |
| 9 | SCPH | Scpharmaceuticals Inc | +1.8% | NEW | New buy |
| 10 | CALC | Calcimedica Inc | +1.7% | NEW | New buy |
| 11 | ANIK | Anika Therapeutics Inc | +1.2% | NEW | New buy |
| 12 | RIGLUSD | Rigel Pharmaceuticals Inc | +1.2% | NEW | New buy |
| 13 | AYTU | Aytu Biopharma Inc | +0.6% | — | Unchanged |
| 14 | TORCEUR | Adicet Bio Inc | +0.3% | NEW | New buy |
| 15 | ADMA | Adma Biologics Inc | -0.1% | -62.84% | Trim |
| 16 | XGN | Exagen Inc | -0.1% | -42.57% | Trim |
| 17 | ATYR | Atyr Pharma Inc | -0.3% | EXIT | Sold out |
| 18 | RZLT | Rezolute Inc | -0.9% | -95.61% | Trim |
| 19 | AVIR | Atea Pharmaceuticals Inc | -1.1% | EXIT | Sold out |
| 20 | IOBTQ | Io Biotech Inc | -1.1% | -90.63% | Trim |
| 21 | SCYXEUR | Scynexis Inc | -1.2% | -92.94% | Trim |
| 22 | XERS | Xeris Biopharma Holdings Inc | -5% | -89.93% | Trim |
| 23 | QDEL | Quidelortho CORP | -14.3% | EXIT | Sold out |
| 24 | AMLX | Amylyx Pharmaceuticals Inc | -15.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Stonepine Capital Management, LLC reported a total U.S. public equity portfolio value of $177.3M across 20 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EOLS, ADMA, ALIMERA SCIENCES INC) accounted for 55.4% of total reported equity market value during Q1 2024.
Top New Position Initiated
RVNCEUR
市值: $9.7M
Top Position Liquidated / Trimmed
AMLX
前期市值: $36.8M
During Q1 2024, Stonepine Capital Management, LLC's top holdings by market value included EOLS (29.7%)、ADMA (17.9%)、ALIMERA SCIENCES INC (12.5%). The largest single position, EOLS, represented 29.7% of total portfolio value.
In Q1 2024, Stonepine Capital Management, LLC made 23 total portfolio adjustments, initiating 8 new buys, adding to 4 positions, trimming 7 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.